心筋症(Cardiomyopathy)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cardiomyopathy Overview 9
Therapeutics Development 10
Pipeline Products for Cardiomyopathy – Overview 10
Pipeline Products for Cardiomyopathy – Comparative Analysis 11
Cardiomyopathy – Therapeutics under Development by Companies 12
Cardiomyopathy – Therapeutics under Investigation by Universities/Institutes 14
Cardiomyopathy – Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Cardiomyopathy – Products under Development by Companies 18
Cardiomyopathy – Products under Investigation by Universities/Institutes 20
Cardiomyopathy – Companies Involved in Therapeutics Development 21
Array BioPharma Inc. 21
Beech Tree Labs, Inc. 22
Bioheart, Inc. 23
Celladon Corporation 24
Gilead Sciences, Inc. 25
Kasiak Research Pvt. Ltd. 26
LG Life Sciences, Ltd. 27
miRagen Therapeutics, Inc. 28
MyoKardia, Inc. 29
Neurimmune Holding AG 30
Novartis AG 31
Nyken BV 32
Sanofi 33
Shire Plc 34
Stemedica Cell Technologies, Inc. 35
Stempeutics Research Private Limited 36
Torrent Pharmaceuticals Limited 37
Vericel Corporation 38
Cardiomyopathy – Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
AdipoCell – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ARRY-797 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
binimetinib – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CAP-1002 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Cyndacel-M – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Drug for Cardiomyopathy – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Drugs to Activate Nrf2 for Diabetic Cardiomyopathy – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Gene Therapy for Cardiomyopathy – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Gene therapy to Activate mSCF for Ischemic Cardiomyopathy – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
GLP-1 – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
GS-6615 – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ixmyelocel-T – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
JR-100 – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
LC-280126 – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Mesenchymal Stem Cells – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
MGN-9103 – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Monoclonal Antibodies for Cardiovascular Diseases – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
MYK-461 – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
NI-301 – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
NYK-1112 – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
perhexiline maleate – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Recombinat Proten to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Refacell-DCM – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
SHP-627 – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecule for Dilated Cardiomyopathy – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Stempeucel – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
TRC-120038 – Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Cardiomyopathy – Recent Pipeline Updates 88
Cardiomyopathy – Dormant Projects 105
Cardiomyopathy – Product Development Milestones 106
Featured News & Press Releases 106
Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T 106
Nov 20, 2014: University of Pennsylvania Doses First Patient in Phase IIa Clinical Trial Using CardioCell’s Stem Cell Therapy to Treat Chronic Heart Failure Due to Non-Ischemic Cardiomyopathy 106
Nov 12, 2014: Bioheart Announces First Intracoronary Implantation of Adipose Stem Cells in Azerbaijan 107
Oct 27, 2014: Celladon Corporation Announces Publication of Data From Its Stem Cell Factor Gene Therapy Program in Circulation Heart Failure 107
Aug 22, 2014: Treatment With Aastrom’s Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic Dilated Cardiomyopathy 108
Apr 02, 2014: FDA Grants IND Approval for Phase IIa Clinical Trial Using CardioCell’s itMSC Therapy to Treat Dilated Chronic Heart Failure 109
Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia 110
Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack 110
Sep 16, 2013: Aastrom Clinical Trial Application for Phase 2b ixCELL-DCM Study of ixmyelocel-T Approved in Canada 111
Apr 19, 2013: Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T 111
Appendix 112
Methodology 112
Coverage 112
Secondary Research 112
Primary Research 112
Expert Panel Validation 112
Contact Us 112
Disclaimer 113